LXRX PE Ratio & Valuation, Is LXRX Overvalued

Historical Valuation

Lexicon Pharmaceuticals Inc (LXRX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 34.31 is considered Overvalued compared with the five-year average of -4.22. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 0.84 to 1.27 according to relative valuation method. Compared to the current price of 1.59 USD , Lexicon Pharmaceuticals Inc By Overvalued By 24.86%.

Relative Value

Fair Zone

0.84-1.27

Current Price：1.59

24.86%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lexicon Pharmaceuticals Inc (LXRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lexicon Pharmaceuticals Inc (LXRX) has a current Price-to-Book (P/B) ratio of 6.26. Compared to its 3-year average P/B ratio of 3.18, the current P/B ratio is approximately 97.10% higher. Relative to its 5-year average P/B ratio of 3.58, the current P/B ratio is about 74.98% higher. Lexicon Pharmaceuticals Inc (LXRX) has a Forward Free Cash Flow (FCF) yield of approximately -10.07%. Compared to its 3-year average FCF yield of -38.61%, the current FCF yield is approximately -73.91% lower. Relative to its 5-year average FCF yield of -31.62%, the current FCF yield is about -68.15% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LXRX competitors is 11.97, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX.O) exhibits a P/S ratio of 34.31, which is 186.76% above the industry average. Given its robust revenue growth of -79.31%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LXRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LXRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LXRX currently overvalued or undervalued?

Lexicon Pharmaceuticals Inc (LXRX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 34.31 is considered Overvalued compared with the five-year average of -4.22. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 0.84 to 1.27 according to relative valuation method. Compared to the current price of 1.59 USD, Lexicon Pharmaceuticals Inc is Overvalued By 24.86%.

What is Lexicon Pharmaceuticals Inc (LXRX) fair value?

LXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 0.84 to 1.27 according to relative valuation method.

How does LXRX's valuation metrics compare to the industry average?

The average P/S ratio for LXRX's competitors is 11.97, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX) exhibits a P/S ratio of 34.31, which is 186.76% above the industry average. Given its robust revenue growth of -79.31%, this premium appears unsustainable.

What is the current P/B ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Apr 06 2026?

As of Apr 06 2026, Lexicon Pharmaceuticals Inc (LXRX) has a P/B ratio of 6.26. This indicates that the market values LXRX at 6.26 times its book value.

What is the current FCF Yield for Lexicon Pharmaceuticals Inc (LXRX) as of Apr 06 2026?

As of Apr 06 2026, Lexicon Pharmaceuticals Inc (LXRX) has a FCF Yield of -10.07%. This means that for every dollar of Lexicon Pharmaceuticals Inc's market capitalization, the company generates -10.07 cents in free cash flow.

What is the current Forward P/E ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Apr 06 2026?

As of Apr 06 2026, Lexicon Pharmaceuticals Inc (LXRX) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Lexicon Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Apr 06 2026?

As of Apr 06 2026, Lexicon Pharmaceuticals Inc (LXRX) has a Forward P/S ratio of 34.31. This means the market is valuing LXRX at $34.31 for every dollar of expected revenue over the next 12 months.

LXRX Valuation